Tom Graney, Oxurion CEO
May 9, 2022 10:07 AM EDTUpdated 11:03 AM
R&D

Bel­gian eye biotech gets ham­mered by in­vestors af­ter PhII tri­al fails ef­fi­ca­cy on key end­points

Paul Schloesser

Associate Editor

Bel­gian biotech and pen­ny stock play­er Ox­u­ri­on was al­ready hov­er­ing around the $1.06/share mark this past week on the Eu­ronext stock ex­change in Brus­sels …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times